Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting

Real‐world outcomes among patients with EGFR‐mutated non‐small cell lung cancer treated with EGFR tyrosine kinase inhibitors versus immunotherapy or chemotherapy in the first‐line setting

Abstract Background Despite national guideline recommendations, epidermal growth factor receptor mutated (EGFRm) metastatic non‐small cell lung cancer (mNSCLC) patients may still receive suboptimal treatment in the first line (1L). This study evaluated 1L therapy initiation in relation to biomarker...

Full description

Bibliographic Details
Main Authors: Jon Apple, Rahul Shenolikar, Kevin De Silva, Ping Sun, Alexander Spira
Format: Article
Language:English
Published: Wiley 2023-06-01
Series:Cancer Medicine
Subjects:
biomarkers
chemotherapy
lung cancer
target therapy
tyrosine kinase inhibitors
Online Access:https://doi.org/10.1002/cam4.6052

Internet

https://doi.org/10.1002/cam4.6052

Similar Items